130 related articles for article (PubMed ID: 29397631)
1. Development of epidermal growth factor receptor targeted therapy in pancreatic cancer.
Qing L; Qing W
Minerva Chir; 2018 Oct; 73(5):488-496. PubMed ID: 29397631
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer.
Heeger S
Recent Results Cancer Res; 2008; 177():131-6. PubMed ID: 18084955
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor: is a novel therapeutic target for pancreatic cancer?
Dhar A; Mehta S; Banerjee S; Dhar K; Dhar G; Sengupta K; Ray G; Banerjee SK; Campbell DR
Front Biosci; 2005 May; 10():1763-7. PubMed ID: 15769665
[TBL] [Abstract][Full Text] [Related]
4. Possible role of epidermal growth factor receptors in the therapy of pancreatic cancer.
Aggarwal S; Gupta S; Gupta MK; Murthy RS; Vyas SP
Crit Rev Ther Drug Carrier Syst; 2011; 28(4):293-356. PubMed ID: 21967400
[TBL] [Abstract][Full Text] [Related]
5. Molecular and genetic bases of pancreatic cancer.
Vaccaro V; Gelibter A; Bria E; Iapicca P; Cappello P; Di Modugno F; Pino MS; Nuzzo C; Cognetti F; Novelli F; Nistico P; Milella M
Curr Drug Targets; 2012 Jun; 13(6):731-43. PubMed ID: 22458519
[TBL] [Abstract][Full Text] [Related]
6. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches to target pancreatic cancer.
Porzner M; Seufferlein T
Curr Cancer Drug Targets; 2011 Jul; 11(6):698-713. PubMed ID: 21599630
[TBL] [Abstract][Full Text] [Related]
9. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor-targeted therapy for pancreatic cancer.
Papageorgio C; Perry MC
Cancer Invest; 2007 Oct; 25(7):647-57. PubMed ID: 18027154
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
Bozec A; Peyrade F; Milano G
Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
[TBL] [Abstract][Full Text] [Related]
12. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
13. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
Philip PA; Lutz MP
Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
[TBL] [Abstract][Full Text] [Related]
14. Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy.
Steelman LS; Fitzgerald T; Lertpiriyapong K; Cocco L; Follo MY; Martelli AM; Neri LM; Marmiroli S; Libra M; Candido S; Nicoletti F; Scalisi A; Fenga C; Drobot L; Rakus D; Gizak A; Laidler P; Dulinska-Litewka J; Basecke J; Mijatovic S; Maksimovic-Ivanic D; Montalto G; Cervello M; Milella M; Tafuri A; Demidenko Z; Abrams SL; McCubrey JA
Curr Pharm Des; 2016; 22(16):2358-88. PubMed ID: 26947958
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
16. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling.
Zheng H; Yang L; Kang Y; Chen M; Lin S; Xiang Y; Li C; Dai X; Huang X; Liang G; Zhao C
Mol Carcinog; 2019 Apr; 58(4):565-576. PubMed ID: 30520143
[TBL] [Abstract][Full Text] [Related]
17. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
[No Abstract] [Full Text] [Related]
18. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
Wei F; Zhang Y; Geng L; Zhang P; Wang G; Liu Y
Int J Mol Sci; 2015 Feb; 16(2):3267-82. PubMed ID: 25654224
[TBL] [Abstract][Full Text] [Related]
19. Rhein sensitizes human pancreatic cancer cells to EGFR inhibitors by inhibiting STAT3 pathway.
Yang L; Lin S; Kang Y; Xiang Y; Xu L; Li J; Dai X; Liang G; Huang X; Zhao C
J Exp Clin Cancer Res; 2019 Jan; 38(1):31. PubMed ID: 30674340
[TBL] [Abstract][Full Text] [Related]
20. EGFR-targeted therapies in the post-genomic era.
Xu MJ; Johnson DE; Grandis JR
Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
